Advertisement

Organisation › Details
Shinobi Therapeutics Inc.
Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8aß iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system. *
![]() |
Start | 2023-12-12 existent (s-offbef) |
Group | Shinobi Therapeutics (Group) | |
Today | Shinobi Therapeutics (Group) | |
Predecessor | University of California, San Francisco (UCSF) | |
![]() |
Industry | Katana iPS-T cell therapy paltform (CD8aß iPS-T cell platform) |
Industry 2 | off-the-shelf iPS-T cell therapy against GPC3+ cancers (Shinobi Therapeutics) | |
![]() |
Person | Kemp, Daniel M. (Dan) (Shinobi Therapeutics 202312 CEO formerly CEO of Wugen) |
![]() |
Region | South San Francisco, CA |
Country | United States (USA) | |
City | n. a. South San Francisco, CA | |
Address record changed: 2023-12-22 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Shinobi Therapeutics Inc.. (12/12/23). "Press Release: Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform". San Francisco, CA & Kyoto. | ||
Record changed: 2024-06-07 |
Advertisement

More documents for Shinobi Therapeutics (Group)
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top